Superior in eyes of the beholder

After a Phase II trial of PF-03187207 failed to show statistically significant superiority to its market-leading Xalatan latanoprost in glaucoma last month, Pfizer Inc. decided not to move forward with Phase III development. But partner NicOx S.A. believes the marginal improvements in reduced intraocular pressure (IOP) provided by PF-03187207 are sufficient to warrant further development.

Some clinicians contacted by BioCen-tury suggested that in the absence of more marked improvements, the compound may be a niche product as the market leader heads toward generic status...